NCT07081256View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.

PHASE3RecruitingINTERVENTIONAL
Enrollment

664

Participants

Timeline

Start Date

January 3, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
DRUG

QLM2010 for injection；dexamethasone

QLM2010 for injection；Drug for preventing nausea and vomiting caused by chemotherapy dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy

DRUG

fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone

fosaprepitant dimeglumine for injection: Drug for preventing nausea and vomiting caused by chemotherapy palonosetron hydrochloride injection: Drug for preventing nausea and vomiting caused by chemotherapy dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy

Trial Locations (1)

Unknown

RECRUITING

Zhe jiangCancer Hospital, Hangzhou

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY